Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers


  • Presage utilizes its CIVO intratumoral microdosing platform to evaluate Celgene’s early stage products in P-0 trial
  • The collaboration follows safety & feasibility of CIVO in sarcoma patients, a clinical trial conducted by Presage which demonstrated well-tolerated data and the results are expected to be published in H2’19
  • Presage’s CIVO platform is an intratumoral microdosing platform used to evaluate patients’ unique responses to microdoses of multiple cancer drugs and is helpful in the drug development process

Click here to read full press release/ article | Ref: PRNewsWire | Image: Wall Street Journal